Drugs / BNZ-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03532958 | Oct 2021 → Nov 2022 | alopecia areata, alopecia totalis, alopecia universalis | Equillium | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNZ-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03532958 ↗ |
| Action | Inhibit | “PEGylated peptide inhibitor of IL-2, IL-9, and IL-15” NCT03532958 ↗ |
| Modality | Peptide | “PEGylated peptide inhibitor of IL-2, IL-9, and IL-15” NCT03532958 ↗ |
| Route | Intravenous | “administered by slow IV push weekly for 3 months” NCT03532958 ↗ |